Dr. Richard Eglen Joins PerkinElmer to Lead Discovery and Research Reagents Business
Eglen joins PerkinElmer from DiscoveRx, where he held the positions of chief scientific officer and executive vice president for research and development. Prior to that, Eglen worked for more than 20 years in several executive positions within the pharmaceutical, diagnostic and biotech industries.
Eglen has a Ph.D. in Molecular Pharmacology from Trent University in Nottingham, United Kingdom. He has been published in more than 250 scientific papers and books and holds several patents, many of which focus on key drug discovery targets such as GPCRs, kinases and ion channels. He also holds several patents relating to novel technologies for enabling drug discovery and other types of research. Eglen serves on numerous journal editorial boards and is a board member of the Society for BioMolecular Sciences (SBS).
Topics
Organizations
Other news from the department people
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.